Women younger than 35 years with low-grade serous carcinoma of the ovary (LGSOC) and peritoneum (LGSPC) and those with persistent disease at completion of primary therapy have the worst outcomes, according to a study of 350 women diagnosed with LGSOC or LGSPC. Researchers found:

• Median progression-free survival was 28.1 months.

• Median overall survival was 101.7 months.

• Those older than 35 years at diagnosis had a 43% reduction in likelihood of dying compared to those 35 years or younger.

• Having disease present after completing primary therapy was associated with a hazard ratio of dying of 1.78, compared with being disease free.

• In a separate cohort, women with LGSPC had a 41% decreased chance of dying, compared to those with LGSOC.

Citation: Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. [Published online ahead of print July 20, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.0873.